Strong revenue, margin miss signals execution risk

EBITDA 47 Cr on 189.7 Cr revenue = 24.7% margin, 800-1000 bps below 33-35% guidance

Revenue 189.7 Cr YoY +30.8%, corroborated; but QoQ -31.4% shows severe Q1 dip

Even with 10.5 Cr benefit, EBITDA margin reaches only ~26.2%, still 700 bps below 33-35%

Delivered PAT margin 12.5%, minor rounding variance

Demand confirmed strong; deferral was timing, not loss. Recovery claim plausible but not yet proven

Prior: 33-35%. New: 32-35% (one instance). Implies floor acknowledgment. Q1 at 25% signals full-year recovery path is steep.

Originally planned big August shutdown across blocks A-D scrapped; phased debottlenecking instead. Protects Q2 production given Q1 loss.

Already launched two anesthetic products Q2. EU audit moved to Nov 2026 (confirmed vs prior ambiguity). Finished formulation ramp to follow audit clearance.

Planned maintenance build now being liquidated over 3-4 qtrs. Working capital drag confirmed, product mix flexibility constrained near-term.

Solar subsidy: govt collecting ₹4.5-5 Cr backpay (Mar-Jul) as one-time; future increases will be passed to customers on PO basis. Water resolved by late monsoon onset.

Ground broken; boundary walls underway in Isambe. API block first (2.5 yr to 40% completion per MIDC rule). Formulation phase-2 later. No near-term bottleneck.

Each psychotropic consignment needs unique CBN export auth. Lapse was one shipment only; new auth received; matter sub judice. Non-recurrence via SAP implementation planned.

DSM very stable, near peak volumes. Pharma validation done; dedicated facility operational. Traction very positive.

Mix impact + Europe sales lower + production losses = multiple factors. Backward integration at 72%; mix shift was seasonal/temporary.

Opportunity is large; SAP live in 4-5 months; R&D team 20-30 to 70; automization ongoing. Potential to grow beyond 20% if regulatory approvals fast.

20% CAGR baseline. Beyond FY27: multiple verticals (CMO, finished formulation, capacity), no specific FY28 number. Growth >20% possible.

Cash 150 Cr FDs/MF. Phase-1 200 Cr (API + utility blocks). Phase-2 similar or larger. First 40% completion ~2.5 years from now.

Q1 revenue 189.7 Cr implies ~270 Cr/qtr needed; Q1 was 31% YoY growth. Non-linear due to product ramps, water loss recovery

Q1 at 25% signals recovery path is steep. Mgmt claims temporary shocks; claims to pass cost inflation to customers on PO basis

Structural margin cap acknowledged by mgmt; finished formulation and CDMO projects slower to scale than API

Approved by MIDC; ground broken; boundary wall construction underway. First focus on API capacity (Lote approaching saturation)

Smaller debottlenecking vs Patalganga; timeline after annual maintenance phased approach

Lote facility depends on Koyna River; monsoon delayed Q1, causing ₹35 Cr deferral. Water recycling project in early stages; not yet mitigated.

Maharashtra solar subsidy policy change Jan 2026 caused ₹8 Cr EBITDA impact Q1. ToD rate reduction adds structural cost. Backpay (₹4.5-5 Cr) is one-time; forward increases ongoing.

One psychotropic (narcotic) product consignment shipped with expired export authorization due to 2-day human error by logistics dept (GM). Shipping bill under investigation. Matter sub judice. Mgmt claims 'miniscule value' but risk to broader export approvals if precedent tightened.

Closing inventory at ₹230-240 Cr (4.2x monthly revenue ~57 Cr). Planned for Aug Q2 maintenance shutdown now cancelled; phased debottlenecking instead. Mgmt to liquidate over 3-4 quarters. High inventory constrains cash & product mix flexibility.

Q1 EBITDA margin 25% vs 33-35% guidance is 800-1000 bps miss. Mgmt cites ₹10.5 Cr external shocks, but even with benefit, margin ~26-27%, still 600-700 bps short. Mix shifts (product ramps at lower initial margins, CDMO lower-margin projects), manufacturing inefficiencies, and competitive pressures not fully disclosed.